Results 201 to 210 of about 24,907 (259)

Circulating Omega‐3 Fatty Acids and Cardiometabolic Outcomes: A Systematic Review of Publications From UK Biobank

Lipids, EarlyView.
ABSTRACT Studies have shown that omega‐3 fatty acids may protect against cardiovascular diseases (CVDs) and related metabolic conditions. UK Biobank is a large cohort study that includes data on plasma omega‐3 fatty acids at study entry and health outcomes during the follow‐up period.
Warda Tul Firdous, Philip C. Calder
wiley   +1 more source

A Gap Analysis of Deep Brain Stimulation for Childhood‐Onset Movement Disorders

Movement Disorders, EarlyView.
Abstract Background Deep brain stimulation (DBS) is an established and increasingly utilized therapy for childhood‐onset movement disorders. However, pediatric DBS poses unique challenges that are not adequately addressed by adult‐derived paradigms. Objective To identify key gaps in the current use of DBS in childhood‐onset movement disorders and to ...
Daniela Munoz‐Chesta, Carolina Gorodetsky, Todd M. Herrington, Angela L. Hewitt, Daniel E. Lumsden, Jennifer O'Malley, Terence Sanger   +6 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood, Jacinta R. Macdonald, Christian Anzenhofer, Tina S. Skinner‐Adams, Robert C. Reid, Thomas Kurz, David P. Fairlie, Katherine T. Andrews   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Progestogens in combined oral contraceptives for contraception

2004
The progestogen component of oral contraceptives (OC) has undergone changes since it was first recognised that their chemical structures could influence the spectrum of minor adverse and beneficial effects. The major determinants of OCs are effectiveness, cycle control and common side effects.
N, Maitra, R, Kulier, K W M, Bloemenkamp, F M, Helmerhorst, A M, Gülmezoglu   +4 more
openaire   +2 more sources

The benefits of combined oral contraceptives

BJOG: An International Journal of Obstetrics & Gynaecology, 1989
The benefits of combined oral contraceptives are put into perspective considering their effectiveness as a contraceptive actual risks for breast ovarian endometrial and cervical cancer and effects of reproductive and other body systems. Combined oral contraceptives are the best contraceptives available except for injectable progestogens therefore they
openaire   +2 more sources

Combined oral contraceptives: risks and benefits

British Medical Bulletin, 1993
By the age of 25 years, more than 95% of sexually active women have been exposed to combined oral contraceptives (COCs). Any effects associated with their use, therefore, carry important public health implications. COCs exert major protective effects against ovarian and endometrial cancer, which continue many years after cessation of use. COCs increase
M, Thorogood, L, Villard-Mackintosh
openaire   +2 more sources

Combined oral contraceptives and liver disease

Contraception, 1997
Although some information is available about the risk of liver tumors associated with combined oral contraceptive use, little is known about the relationship with other hepatic problems. Data from two large long-term observational studies, the Royal College of General Practitioners (RCGP) Oral Contraception Study and the Oxford-Family Planning ...
P C, Hannaford, C R, Kay, M P, Vessey, R, Painter, J, Mant   +4 more
openaire   +2 more sources

Current perspectives on combination oral contraceptives

American Journal of Health-System Pharmacy, 1984
The physiology, mechanism of action, therapeutic use and effectiveness, potential risks, and noncontraceptive benefits of combination oral contraceptives (COCs) are reviewed with a discussion of patient considerations and management guidelines for common side effects. Modifications of the earlier COCs have both a lower estrogen and progestogen content.
M A, Smith, E Q, Youngkin
openaire   +2 more sources

Combined oral contraceptives: venous thrombosis

Cochrane Database of Systematic Reviews, 2013
Combined oral contraceptive (COC) use has been associated with venous thrombosis (VT) (i.e., deep venous thrombosis and pulmonary embolism). The VT risk has been evaluated for many estrogen doses and progestagen types contained in COC but no comprehensive comparison involving commonly used COC is available.To provide a comprehensive overview of the ...
Bastos, M. de, Stegeman, B.H., Rosendaal, F.R., Vlieg, A.V., Helmerhorst, F.M., Stijnen, T., Dekkers, O.M.   +6 more
openaire   +3 more sources

The combined oral contraceptive pill

InnovAiT: Education and inspiration for general practice, 2022
The combined oral contraceptive pill (COCP) has been a popular choice of contraception since it was first introduced in 1961. There are numerous varieties of COCP and tailored regimes allow patients more choice and opportunities to adapt contraception to suit individual needs.
openaire   +1 more source